TIBER CREEK GROUP

Lobbying for VERTEX PHARMACEUTICALS · Global biotechnology company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Jan 17, 2026

Bills named in this filing 2

Lobbying activity 2

Health Issues

Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.

Defense

Issues related to opioid alternatives; Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.